Company Filing History:
1 out of 1 
1 out of 10 Years Active: 2009
Title: The Innovative Contributions of Gabriela Stiegler in HIV Research
Introduction: Gabriela Stiegler, an accomplished inventor based in Fels am Wagram, Austria, has made significant strides in the field of HIV research. With a focus on the development of monoclonal antibodies, Stiegler has created innovative solutions aimed at combating this challenging virus. She holds two patents that exemplify her dedication and expertise in immunobiology.
Latest Patents: Stiegler's recent innovations include two notable patents that focus on anti-HIV antibodies. The first patent involves an "Anti-idiotypic monoclonal antibody reactive with HIV neutralizing antibody 2F5." This invention relates to Ab2-type anti-idiotypic antibodies and fragments that mimic HIV-1 epitopes, making them crucial in eliciting neutralizing antibodies against HIV. It also introduces a hybridoma cell line, 3H6, expressing the anti-idiotypic antibody, alongside pharmaceutical compositions containing it.
Her second patent pertains to an "IGG1 monoclonal antibody with anti-HIV neutralizing activity." This invention showcases the mAb 4E10-IgG1, which possesses an HIV-1 neutralizing potency similar to mAb 2F5 and 2G12. It binds to a newly identified conserved epitope and demonstrates the ability to neutralize various strains of HIV, including those resistant to other antibodies. These contributions highlight Stiegler's innovative spirit and the potential impact of her work on HIV therapies.
Career Highlights: Gabriela Stiegler has worked with prominent organizations such as Polymun Scientific Immunobiologische Forschung GmbH. Her work at these institutions has allowed her to leverage her skills in immunobiology and contribute to groundbreaking innovations in antibody development. Her expertise in the field is reflected through her patents, which pave the way for future advancements in medical treatments for HIV.
Collaborations: Throughout her career, Stiegler has collaborated with esteemed colleagues, including Renate Kunert and Hermann W. Katinger. These partnerships have enhanced her research endeavors and have contributed to the successful development of her patented inventions, showcasing the power of teamwork in the scientific landscape.
Conclusion: Gabriela Stiegler's contributions to HIV research through her innovative patents reflect her commitment to advancing medical science. Her work not only highlights her expertise and creativity but also opens new avenues for therapeutic interventions in the fight against HIV. As an inventor, Stiegler stands at the forefront of immunobiological research, inspiring future innovations and enhancing our understanding of virus-neutralizing antibodies.